Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Impel Pharmaceuticals
Impel Pharmaceuticals Announces Exploration of Strategic Alternatives
October 05, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Society
June 15, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
May 12, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer
May 10, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023
May 05, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals Presents New Data at AAN 2023 Suggesting Trudhesa® Nasal Spray is Safe to Use When Co-Administered With Commonly Prescribed Migraine Medications
April 26, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors
April 12, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray for Treatment of Acute Migraine at 2023 American Academy of Neurology Annual Meeting
April 11, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 24, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023
March 17, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March
March 03, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals Announces Strategic Repriortization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity
February 22, 2023
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals to Participate in Guggenheim 4th Annual Immunology and Neurology Day
November 08, 2022
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Impel Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
November 07, 2022
From
Impel Pharmaceuticals
Via
GlobeNewswire
Tickers
IMPL
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.